Dexcel Pharma Technologies Ltd. Protalix Bio Therapeutics, Inc. (PLX) insider trading activity

Dexcel Pharma Technologies Ltd. is > 10% Shareholder of Protalix BioTherapeutics, Inc.. Currently has a direct ownership of 3.64 Million shares of PLX, which is worth approximately $6.37 Million. The most recent transaction as insider was on Jun 03, 2021, when has been sold 857,506 shares (Common Stock) at a price of $2.25 per share, resulting in proceeds of $1,929,388. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 3.64M

0% 3M change

0% 12M change

Total Value Held $6.37 Million

Dexcel Pharma Technologies Ltd. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Jun 03 2021	SELL Open market or private sale	$1,929,388 $2.25 p/Share	857,506 Reduced 19.08%	3,637,314 Common Stock
Jun 02 2021	SELL Open market or private sale	$156,700 $2.56 p/Share	61,211 Reduced 1.34%	4,494,820 Common Stock

Also insider at

ROIV

Roivant Sciences Ltd. Healthcare

> 10% Shareholder

DPT